Guangzhou Wondfo Biotech - Public Comps and Valuation Multiples

Guangzhou Wondfo Biotech Overview

About Guangzhou Wondfo Biotech

Guangzhou Wondfo Biotech Co Ltd manufactures medical diagnostic tests. Its products include immunodiagnostic rapid test kits, including fertility, which include pregnancy HCG, ovulation LH, and others. The company's products are used in a clinical test, field test, and personal health management, among others.

Founded

1992

HQ

Employees

n/a

Website

wondfo.com.cn

Sectors

Medical Imaging & Diagnostics
Laboratory Services
HealthTech

Financials

LTM Revenue $358M

Last FY EBITDA $134M

EV

$1.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Guangzhou Wondfo Biotech Financials

As of December 2025, Guangzhou Wondfo Biotech reported last 12-month revenue of $358M.

In the same period, Guangzhou Wondfo Biotech generated $225M in LTM gross profit and $36.4M in net income.

See Guangzhou Wondfo Biotech valuation multiples based on analyst estimates

Guangzhou Wondfo Biotech P&L

In the most recent fiscal year, Guangzhou Wondfo Biotech reported revenue of $440M and EBITDA of $134M.

Guangzhou Wondfo Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Guangzhou Wondfo Biotech valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$358M	XXX	$440M	XXX	XXX	XXX
Gross Profit	$225M	XXX	$282M	XXX	XXX	XXX
Gross Margin	63%	XXX	64%	XXX	XXX	XXX
EBITDA	n/a	XXX	$134M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	30%	XXX	XXX	XXX
EBIT	$38.0M	XXX	$94.4M	XXX	XXX	XXX
EBIT Margin	11%	XXX	21%	XXX	XXX	XXX
Net Profit	$36.4M	XXX	$80.6M	XXX	XXX	XXX
Net Margin	10%	XXX	18%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Guangzhou Wondfo Biotech including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $358M. In the most recent fiscal year, Guangzhou Wondfo Biotech achieved $440M in revenue and $134M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$358M	Analyst estimates available to subscribers	$440M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$225M	Analyst estimates available to subscribers	$282M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	62.8% gross margin	Analyst estimates available to subscribers	64.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	$134M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	30.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$38.0M	Analyst estimates available to subscribers	$94.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	10.6% EBIT margin	Analyst estimates available to subscribers	21.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$36.4M	Analyst estimates available to subscribers	$80.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	10.2% net profit margin	Analyst estimates available to subscribers	18.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Guangzhou Wondfo Biotech

This financial data table provides comprehensive performance metrics for Guangzhou Wondfo Biotech, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Guangzhou Wondfo Biotech generated $358M in revenue over the last twelve months.
Gross profit for the last twelve months was $225M.
Net income over the last twelve months reached $36.4M.

Fiscal Year Performance

In the most recent fiscal year, Guangzhou Wondfo Biotech reported $440M in total revenue.
Fiscal year EBITDA was $134M.
The company maintained a gross profit margin of 64.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 30.4%.
Net profit margin reached 18.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Guangzhou Wondfo Biotech. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Guangzhou Wondfo Biotech Stock Performance

Guangzhou Wondfo Biotech has current market cap of CNY 10.3B (or $1.5B), and EV of CNY 9.3B (or $1.3B).

Market Cap Evolution

Guangzhou Wondfo Biotech Stock Data

As of January 19, 2026, Guangzhou Wondfo Biotech's stock price is CNY 22 (or $3).

See Guangzhou Wondfo Biotech trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.3B	$1.5B	XXX	XXX	XXX	XXX	$0.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Guangzhou Wondfo Biotech Valuation Multiples

Guangzhou Wondfo Biotech's trades at 3.7x EV/Revenue multiple, and 10.0x EV/EBITDA.

See valuation multiples for Guangzhou Wondfo Biotech and 15K+ public comps

Guangzhou Wondfo Biotech Financial Valuation Multiples

As of January 19, 2026, Guangzhou Wondfo Biotech has market cap of $1.5B and EV of $1.3B.

Equity research analysts estimate Guangzhou Wondfo Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Guangzhou Wondfo Biotech has a P/E ratio of 40.6x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$1.5B	XXX	$1.5B	XXX	XXX	XXX
EV (current)	$1.3B	XXX	$1.3B	XXX	XXX	XXX
EV/Revenue	3.7x	XXX	3.7x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	10.0x	XXX	XXX	XXX
EV/EBIT	35.1x	XXX	35.1x	XXX	XXX	XXX
EV/Gross Profit	5.9x	XXX	n/a	XXX	XXX	XXX
P/E	40.6x	XXX	40.6x	XXX	XXX	XXX
EV/FCF	9.0x	XXX	9.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Guangzhou Wondfo Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Guangzhou Wondfo Biotech Margins & Growth Rates

Guangzhou Wondfo Biotech's last 12 month revenue growth is 13%

Guangzhou Wondfo Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Guangzhou Wondfo Biotech's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Guangzhou Wondfo Biotech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Guangzhou Wondfo Biotech and other 15K+ public comps

Guangzhou Wondfo Biotech Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	13%	XXX	13%	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	44%	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	8%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	13%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	43%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial